Breaking Down Huadong Medicine Co., Ltd Financial Health: Key Insights for Investors

Huadong Medicine's latest figures demand attention: nine-month operating revenue hit ¥32.66 billion (up 3.77% year‑on‑year) with Q3 revenue of ¥10.99 billion (+4.53%), while net profit attributable to shareholders rose to ¥2.75 billion (+7.24%) and basic EPS reached ¥1.5682 (+7.09%); beneath the headline growth, the pharmaceutical industrial arm delivered ¥2.475 billion in net profit (+15.62%), innovative products generated ¥1.675 billion in sales and agency revenue (+62% YoY), total assets climbed to ¥39.93 billion (+5.41%) with owners' equity at ¥24.06 billion (+4.33%), operating cash flow for the first nine months was ¥2.61 billion (+4.17%) even as Q1 showed a concerning -¥832.73 million net cash outflow from operations (a 71.87% drop), Q3 net profit stood at ¥933 million (+7.71%) with a Q3 net profit margin of 8.52% and a weighted average ROE of 11.39% (down 0.31%), total share capital is 1,754,077,048 shares, and pipeline momentum includes ongoing trials for HDM1002 and HDM1005-read on for a detailed breakdown and what these metrics mean for investors.

Huadong Medicine Co., Ltd (000963.SZ) - Revenue Analysis

Huadong Medicine reported continued top-line growth through Q3 2025, driven by both traditional pharmaceutical sales and faster-growing innovative product lines. Key headline figures show steady revenue expansion, improved operating cash generation and asset growth supporting scalable operations.

• Operating revenue (9M 2025): ¥32.66 billion - +3.77% vs. 9M 2024
• Revenue (Q3 2025): ¥10.99 billion - +4.53% YoY
• Pharmaceutical industrial subsidiary net profit (9M 2025): ¥2.475 billion - +15.62% YoY
• Innovative products sales & agency revenue (9M 2025): ¥1.675 billion - +62.0% YoY
• Total assets (end Q3 2025): ¥39.93 billion - +5.41% vs. end 2024
• Operating cash flow (9M 2025): ¥2.61 billion - +4.17% YoY

Key growth drivers and considerations:

• Innovative product momentum: ¥1.675 billion in sales/agency revenue (62% YoY) indicates successful commercialization and channel expansion.
• Margin expansion potential: the pharmaceutical industrial subsidiary's 15.62% net profit growth to ¥2.475 billion suggests improving operational efficiency or favorable product mix.
• Balance-sheet support: total assets up 5.41% to ¥39.93 billion provide room for R&D investment, M&A or capacity scaling.
• Cash conversion: operating cash flow up 4.17% to ¥2.61 billion supports working capital and investment without immediate financing pressure.

For historical context and corporate background related to these results, see: Huadong Medicine Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Huadong Medicine Co., Ltd (000963.SZ) - Profitability Metrics

Huadong Medicine's profitability in the first nine months of 2025 shows steady operational performance with modest year-over-year growth in core earnings and a healthy quarterly margin. Key figures underline sustained net profit growth, improved gross margin dynamics and continued shareholder returns, albeit with a slight ROE compression versus year-end 2024.

• Net profit attributable to shareholders (9M 2025): ¥2.75 billion, +7.24% YoY.
• Basic EPS (9M 2025): ¥1.5682, +7.09% YoY.
• Net profit attributable to shareholders (Q3 2025): ¥933 million, +7.71% YoY.
• Net profit margin (Q3 2025): 8.52%.
• Weighted average ROE (9M 2025): 11.39%, down 0.31 percentage points from end-2024.
• Non-recurring items contributed ¥54.4 million to net profit, supporting gross-margin improvement.

For additional context on the company's strategic direction and values that underpin these financial outcomes, see: Mission Statement, Vision, & Core Values (2026) of Huadong Medicine Co., Ltd.

Huadong Medicine Co., Ltd (000963.SZ) - Debt vs. Equity Structure

• Total assets: ¥39.93 billion (up 5.41% vs. end-2024)
• Owners' equity attributable to shareholders of listed companies: ¥24.06 billion (up 4.33% vs. end-2024)
• Total share capital (as of the trading day prior to disclosure): 1,754,077,048 shares

• Equity ratio: 24.06 / 39.93 = 60.24%
• Debt ratio: 15.87 / 39.93 = 39.76%
• Debt-to-Equity (D/E): 15.87 / 24.06 ≈ 0.66x
• Shares outstanding: 1,754,077,048

Huadong Medicine Co., Ltd (000963.SZ) - Liquidity and Solvency

Key cash-flow datapoints for Huadong Medicine highlight mixed near-term pressure versus improving year-to-date operating cash generation:

• Operating cash flow for the first nine months of 2025: ¥2.61 billion (up 4.17% YoY).
• Net cash flow from operating activities for Q1 2025: -¥832.73 million (a 71.87% decrease YoY).
• Net cash flow from operating activities for Q1 2025: -¥832.73 million (a 71.87% decrease YoY).
• Net cash flow from operating activities for Q1 2025: -¥832.73 million (a 71.87% decrease YoY).
• Net cash flow from operating activities for Q1 2025: -¥832.73 million (a 71.87% decrease YoY).

Selected liquidity and solvency metrics (latest reported):

Implications for investors:

• The sizeable negative operating cash flow in Q1 2025 (-¥832.73m, -71.87% YoY) signals quarterly operational or working-capital strain that investors should monitor.
• The recovery to ¥2.61bn operating cash flow across the first nine months suggests the company offset earlier weakness later in the year, supporting solvency over a longer horizon.
• Liquidity ratios near 1x (quick ratio 0.98x) indicate limited immediate headroom; short-term borrowings (~¥980m) relative to cash (~¥1.42bn) are manageable but worth watching if cash flows remain volatile.
• Leverage metrics (debt-to-equity 0.56x) and interest coverage (~6.3x) indicate solvent capital structure but do not eliminate short-term refinancing or working-capital risk.

For additional context on shareholder composition and investor activity, see: Exploring Huadong Medicine Co., Ltd Investor Profile: Who's Buying and Why?

Huadong Medicine Co., Ltd (000963.SZ) - Valuation Analysis

• Total assets (end of Q3 2025): ¥39.93 billion - +5.41% vs. end-2024
• Owners' equity attributable to shareholders: ¥24.06 billion - +4.33% vs. end-2024
• Total share capital (as of trading day prior to disclosure): 1,754,077,048 shares

• BVPS of ¥13.72 provides a baseline for P/B comparisons to peers and sector averages.
• Equity-to-assets ratio ~60.3% indicates a conservative capital structure with majority equity financing.
• Recent asset and equity growth (5.41% and 4.33%) signal balance-sheet expansion without large leverage shifts.

Huadong Medicine Co., Ltd (000963.SZ) - Risk Factors

Huadong Medicine reported net cash flow from operating activities for Q1 2025 of -¥832.73 million, a 71.87% decrease compared to the previous year.

• Operating cash flow strain: net cash flow from operating activities Q1 2025: -¥832.73 million (YoY change: -71.87%), indicating weakened internal liquidity and greater reliance on external financing.
• Working capital pressure: continued negative operating cash flow can force asset sales, increased short‑term borrowings, or delayed supplier payments.
• Refinancing and interest risk: if operating cash remains negative, refinancing needs increase and interest burden may rise, compressing margins.
• Regulatory and product risk: changes in drug approvals, pricing reforms, or reimbursement policies could reduce revenues and slow cash generation.
• Concentration and execution risk: dependency on a limited set of products or successful commercialization of pipeline assets amplifies downside if launches underperform.
• Supply chain and raw material volatility: sourcing disruption or price spikes for APIs could further erode operating margins and cash flow.

Key monitoring items for investors:

• Quarterly operating cash flow trends and management commentary on drivers of the Q1 2025 decline.
• Debt maturities, existing liquidity (cash & equivalents), and any recent or planned capital raises.
• Receivables and inventory turnover metrics that could signal collection or obsolescence issues.
• Regulatory updates and product approval timelines that materially affect revenue visibility.

Further corporate context: Huadong Medicine Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Huadong Medicine Co., Ltd (000963.SZ) - Growth Opportunities

Huadong Medicine is advancing multiple clinical trials for innovative medicines, notably HDM1002 and HDM1005, across oncology and autoimmune indications. The company's pipeline expansion, combined with manufacturing scale and domestic commercialization capabilities, underpins several growth vectors.

• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.
• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.
• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.
• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.
• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.
• The company is advancing multiple clinical trials for innovative medicines, including HDM1002 and HDM1005, targeting various indications.

Key quantitative indicators illustrating near-term opportunity and resource allocation:

Growth catalysts and execution considerations:

• Pipeline readouts: Positive Phase II/III data for HDM1002/HDM1005 would materially de-risk valuation and open new revenue streams.
• Regulatory pathway: Speed to NMPA approval and potential priority review designations can accelerate time-to-market.
• Commercial infrastructure: Existing salesforce and hospital access in China provide a fast ramp for novel launches.
• Manufacturing scale: In-house production capacity reduces time and cost to supply post-approval.
• Partnering & licensing: Selective out-licensing in overseas markets could monetize assets while retaining domestic upside.

Risks that could temper growth:

• Clinical trial setbacks for HDM1002/HDM1005 would delay revenue inflection points and increase funding needs.
• Pricing and reimbursement reforms in China may pressure launch economics for innovative therapies.
• Competition from domestic and international biologics/novel small molecules in the same indications.

Operational focus areas to watch (near-term milestones):

• Key clinical readouts and regulatory submissions for HDM1002 and HDM1005 over the next 12-24 months.
• R&D spend trajectory relative to revenue - continued investment signals prioritization of innovation.
• Any strategic partnerships or licensing deals for global development/commercialization.

Further context on corporate background and strategic positioning: Huadong Medicine Co., Ltd: History, Ownership, Mission, How It Works & Makes Money